<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657043</url>
  </required_header>
  <id_info>
    <org_study_id>SGNTV-002</org_study_id>
    <nct_id>NCT03657043</nct_id>
  </id_info>
  <brief_title>A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)</brief_title>
  <official_title>Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study tisotumab vedotin to find out what its side effects are and to see if&#xD;
      it works for platinum-resistant ovarian cancer (PROC). It will test different doses of&#xD;
      tisotumab vedotin that are given at different times. It will also compare the side effects&#xD;
      and ability to treat tumors of these different doses and schedules. In this study, there will&#xD;
      be a safety run-in group of approximately 12 patients that will look at a dose-dense&#xD;
      treatment schedule. In a dose-dense schedule, smaller doses are given more frequently. In&#xD;
      addition to the safety run-in patients, there will be three groups in the study. One group&#xD;
      will get tisotumab vedotin once every 3 weeks (21-day cycles). The two other groups will get&#xD;
      tisotumab vedotin once a week for 3 weeks followed by 1 week off (28-day cycles).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objectives are to evaluate the safety, antitumor activity, and pharmacokinetics of&#xD;
      tisotumab vedotin (TV) administered every 3 weeks or on Days 1, 8, and 15 of every 4-week&#xD;
      cycle (3Q4W) for patients with epithelial ovarian cancer, primary peritoneal cancer, or&#xD;
      fallopian tube cancer that has relapsed within 6 months of the completion of platinum-based&#xD;
      treatment and determined to be platinum resistant. All patients must have PROC and be&#xD;
      eligible for single agent chemotherapy.&#xD;
&#xD;
      The safety run-in period will evaluate the safety of a weekly schedule. The highest dose&#xD;
      level that is considered safe will be the recommended phase 2 dose (RP2D) and will be used in&#xD;
      Part A. In Part A, participants will be randomized in a 1:1 ratio to receive tisotumab&#xD;
      vedotin intravenously (IV) every 3 weeks (Q3W regimen) or the safety run-in RP2D on Days 1,&#xD;
      8, and 15 of every 4-week cycle (weekly regimen; 3Q4W) if a RP2D has been identified.&#xD;
      Participants who enroll in Part B will receive tisotumab vedotin on Days 1, 8, and 15 of&#xD;
      every 4-week cycle (weekly regimen) at a pre-specified dose level, if the dose level is&#xD;
      considered safe and tolerable in the safety run-in period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs) (Safety Run-in only)</measure>
    <time_frame>Up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed objective response rate (ORR) (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Proportion of patients who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events that are Grade 3+, treatment-related, or serious (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed and unconfirmed ORR (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Proportion of patients who achieve a CR or PR according to RECIST v1.1 as assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer Antigen 125 (CA-125) response rate according to Gynecologic Cancer Intergroup (GCIG) criteria (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Proportion of patients who have at least a 50% reduction in CA-125 value from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response according to the Gynecological Cancer Intergroup (GCIG) combined RECIST and CA-125 criteria (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Proportion of patients whose best response is a CR or PR according to the GCIG combined RECIST and CA-125 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD or death due to any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Proportion of patients with complete response (CR), partial response (PR), or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR) (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from the start of study treatment to the first documentation of objective response (CR or PR that is subsequently confirmed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from the start of study treatment to the first documentation of PD or death due to any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from the start of study treatment to date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameter: Cmax (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Maximum observed concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: AUClast (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies (ATA) (Parts A and B)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Safety Run-In (3Q4W Schedule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28-day, 3 dose cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Tisotumab Vedotin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21-day, single dose cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Tisotumab Vedotin (3Q4W Schedule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28-day, 3 dose cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Tisotumab Vedotin (3Q4W Schedule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28-day, 3 dose cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tisotumab vedotin</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Part A: Tisotumab Vedotin</arm_group_label>
    <arm_group_label>Part A: Tisotumab Vedotin (3Q4W Schedule)</arm_group_label>
    <arm_group_label>Part B: Tisotumab Vedotin (3Q4W Schedule)</arm_group_label>
    <arm_group_label>Safety Run-In (3Q4W Schedule)</arm_group_label>
    <other_name>TIVDAK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or&#xD;
             fallopian tube cancer&#xD;
&#xD;
          -  Safety run-in only: PROC. Patients may have received more than 1 prior systemic&#xD;
             treatment regimen in the PROC setting.&#xD;
&#xD;
          -  Part A and Part B only: Patients with PROC who have received 1 to 3 anticancer lines&#xD;
             of therapy overall, including at least 1 line of therapy containing bevacizumab or&#xD;
             biosimilar.&#xD;
&#xD;
               -  Adjuvant ± neoadjuvant are considered 1 line of therapy.&#xD;
&#xD;
               -  Patients may have received a PARP inhibitor or an immuno-oncology (IO) agent; any&#xD;
                  of these regimens are to be considered a line of therapy for the purposes of this&#xD;
                  study if not used as maintenance therapy.&#xD;
&#xD;
               -  Maintenance therapy (including bevacizumab, PARP inhibitors and IOs) will be&#xD;
                  considered part of the preceding line of therapy and not to be counted as a new&#xD;
                  line of therapy.&#xD;
&#xD;
               -  Any chemotherapy regimen change due to toxicity in the absence of disease&#xD;
                  progression is considered as part of the same line of therapy.&#xD;
&#xD;
               -  Hormonal therapy will be not be counted towards the lines of therapy.&#xD;
&#xD;
          -  Measurable disease according to RECIST v1.1 as assessed by the investigator&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Able to provide fresh or archival tissue for biomarker analysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary platinum-refractory disease, defined as disease progression within 2 months of&#xD;
             completion of first line platinum-based therapy&#xD;
&#xD;
          -  Patients with clinical symptoms or signs of gastrointestinal obstruction with the past&#xD;
             6 months or who currently require parenteral nutrition&#xD;
&#xD;
          -  Hematological: Known past or current coagulation defects leading to an increased risk&#xD;
             of bleeding, diffuse alveolar hemorrhage from vasculitis, known bleeding diathesis,&#xD;
             ongoing major bleeding, or trauma with increased risk of life-threatening bleeding&#xD;
             within 8 weeks of trial entry&#xD;
&#xD;
          -  Cardiovascular: Clinically significant cardiac disease including uncontrolled&#xD;
             hypertension, unstable angina, acute myocardial infarction with 6 months of screening,&#xD;
             serious cardiac arrhythmia requiring medication, medical history of congestive heart&#xD;
             failure, or medical history of decreased cardiac ejection fraction of &lt;45%&#xD;
&#xD;
          -  Ophthalmological: Active ocular surface disease at baseline or prior episode of&#xD;
             cicatricial conjunctivitis or Stevens Johnson syndrome&#xD;
&#xD;
          -  Prior treatment with MMAE-derived drugs&#xD;
&#xD;
          -  Inflammatory bowel disease including Crohn's disease and ulcerative colitis&#xD;
&#xD;
          -  Ongoing, acute, or chronic inflammatory skin disease&#xD;
&#xD;
          -  Uncontrolled tumor-related pain&#xD;
&#xD;
          -  Inflammatory lung disease requiring chronic medical therapy&#xD;
&#xD;
          -  Grade 3 or higher pulmonary disease unrelated to underlying malignancy&#xD;
&#xD;
          -  Uncontrolled pleural or pericardial effusions&#xD;
&#xD;
          -  Grade &gt;1 peripheral neuropathy&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Beca, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Cancer Center South Bay</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poudre Valley Health System (PVHS)</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80524</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute at Baptist Health, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri Healthcare / Ellis Fischel Cancer Center</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Chelsea</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, The</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Clinical Trials Management Office</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Hillcrest Hospital</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Maria Middelares</name>
      <address>
        <city>Ghent</city>
        <state>Other</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Lueven</city>
        <state>Other</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg Universite Hospital</name>
      <address>
        <city>Aalborg</city>
        <state>Other</state>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Private</name>
      <address>
        <city>Dublin</city>
        <state>Other</state>
        <zip>D07 WKW8</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Wilton</city>
        <state>Other</state>
        <zip>T12 E8YV</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ramazzini di Carpi</name>
      <address>
        <city>Carpi</city>
        <state>Other</state>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Romagnolo per lo Studio dei Tumori &quot;Dino Amadori&quot;- IRST S.r.l</name>
      <address>
        <city>Meldola</city>
        <state>Other</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>Other</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <state>Other</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino</name>
      <address>
        <city>Rome</city>
        <state>Other</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Other</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala D'Oncologia Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <state>Other</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <state>Other</state>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HM Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <state>Other</state>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Other</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quironsalud Madrid</name>
      <address>
        <city>Pozuelo de Alarcón</city>
        <state>Other</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platinum-resistant</keyword>
  <keyword>Antibody drug conjugate</keyword>
  <keyword>Tisotumab vedotin</keyword>
  <keyword>PROC</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tisotumab vedotin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

